250 related articles for article (PubMed ID: 34046086)
1. Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.
Vakrakou AG; Tzanetakos D; Evangelopoulos ME; Argyrakos T; Tzartos JS; Anagnostouli M; Andreadou E; Koutsis G; Velonakis G; Toulas P; Gialafos E; Dimitrakopoulos A; Psimenou E; Stefanis L; Kilidireas C
Ther Adv Neurol Disord; 2021; 14():17562864211006503. PubMed ID: 34046086
[TBL] [Abstract][Full Text] [Related]
2. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
3. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
[TBL] [Abstract][Full Text] [Related]
4. Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features-A case series.
Boyle T; Fernando SL; Drummond J; Fontes A; Parratt J
Front Neurol; 2023; 14():1092373. PubMed ID: 36816572
[TBL] [Abstract][Full Text] [Related]
5. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
6. Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.
Vakrakou AG; Brinia ME; Svolaki I; Argyrakos T; Stefanis L; Kilidireas C
Front Neurol; 2022; 13():868525. PubMed ID: 35418930
[TBL] [Abstract][Full Text] [Related]
7. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
[TBL] [Abstract][Full Text] [Related]
8. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
[TBL] [Abstract][Full Text] [Related]
9. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
[TBL] [Abstract][Full Text] [Related]
10. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
[TBL] [Abstract][Full Text] [Related]
11. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations.
Li X; Miao X; Wang Y; Sun J; Gao H; Han J; Li Y; Wang Q; Sun C; Liu J
Front Immunol; 2022; 13():1052678. PubMed ID: 36532021
[TBL] [Abstract][Full Text] [Related]
13. Tumefactive multiple sclerosis versus high grade glioma: A diagnostic dilemma.
French H; Fontes-Villalba A; Maharaj M; Naidoo CSY; Bhatia K; Paterson A; Cook R; Parratt J
Surg Neurol Int; 2022; 13():146. PubMed ID: 35509579
[TBL] [Abstract][Full Text] [Related]
14. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.
Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P
J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666
[TBL] [Abstract][Full Text] [Related]
15. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
Di Gregorio M; Torri Clerici VLA; Fenu G; Gaetani L; Gallo A; Cavalla P; Ragonese P; Annovazzi P; Gajofatto A; Prosperini L; Landi D; Nicoletti CG; Di Carmine C; Totaro R; Nociti V; De Fino C; Ferraro D; Tomassini V; Tortorella C; Righini I; Amato MP; Manni A; Paolicelli D; Iaffaldano P; Lanzillo R; Moccia M; Buttari F; Fantozzi R; Cerqua R; Zagaglia S; Farina D; De Luca G; Buscarinu MC; Pinardi F; Cocco E; Gasperini C; Solaro CM; Di Filippo M
Eur J Neurol; 2021 Apr; 28(4):1299-1307. PubMed ID: 33305459
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in Tumefactive demyelinating lesions: A retrospective study.
Plowman RS; Varma H
J Neurol Sci; 2021 Sep; 428():117591. PubMed ID: 34333380
[TBL] [Abstract][Full Text] [Related]
17. Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma.
French HD
Surg Neurol Int; 2021; 12():199. PubMed ID: 34084626
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.
Kobayashi M; Shimizu Y; Shibata N; Uchiyama S
J Neurol; 2014 Oct; 261(10):1902-10. PubMed ID: 25034274
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of pathological characteristics of acute and chronic cerebral tumefactive demyelinating lesions].
Sun C; Liu J; Gui Q; Lu D; Qi X
Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(45):3557-61. PubMed ID: 25622833
[TBL] [Abstract][Full Text] [Related]
20. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
Jeung L; Smits LMG; Hoogervorst ELJ; van Oosten BW; Frequin STFM
Mult Scler Relat Disord; 2020 May; 40():101978. PubMed ID: 32062445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
